Sign in →

Test ID 288PD Programmed Death-Ligand 1 (PD-L1) (28-8), Semi-Quantitative Immunohistochemistry, Manual

Ordering Guidance

For information on selection of programmed cell death 1-ligand 1 (PD-L1) testing, see

Shipping Instructions

Attach the green pathology address label included in the kit to the outside of the transport container.

Necessary Information

A pathology/diagnostic report and a brief history, including primary site of neoplasm, are required.

Specimen Required

Specimen Type: Tissue

Supplies: Pathology Packaging Kit (T554)

Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue

Additional Information: One slide will be stained with hematoxylin and eosin and returned.


If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)

Oncology Test Request

Useful For

Identification of neoplasms expressing programmed cell death 1-ligand 1

Method Name

Immunohistochemistry (IHC)

Reporting Name

PD-L1 (28-8), SemiQuant IHC, Manual

Specimen Type


Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)

Clinical Information

Programmed cell death 1-ligand 1 (PD-L1), also known as B7 homolog 1 (B7-H1) or CD274, is a transmembrane protein involved in the regulation of cell-mediated immune responses through interaction with the receptor programmed death protein-1 (PD-1). PD-L1 has been identified as both a prognostic and theranostic marker in a variety of neoplasms. Overexpression of PD-L1 has been observed in carcinomas of the bladder, lung, gastric and gastroesophageal junction, colon, ovary, breast, kidney, and melanoma.


The results of the test will be reported in form of scores. The scoring system is based on type and origin of tumor. If additional interpretation or analysis is needed, order PATHC / Pathology Consultation along with this test.

Clinical Reference

1. Garcia A, Recondo G, Greco M et al: Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. Heliyon. 2020 Jun;6(6):e04117

2. Kintslera S, Cassataroa MA, Drosch M, Holenya P, Knuechel R, Braunschweig T: Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. Ann Diagn Pathol. 2019 Aug;41:24-37

3. O'Malley DP, Yang Y, Boisot S, et al: Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. Mod Pathol. 2019 Jul;32(7):929-942

4. Koppel C, Schwellenbach H, Zielinski D, et al: Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod Pathol. 2018 Nov;31(11):1630-1644

5. Phillips T, Simmons P, Inzunza HD, et al: Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-549

Day(s) Performed

Monday through Friday

Report Available

5 to 7 days

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
288PD PD-L1 (28-8), SemiQuant IHC, Manual 85148-5


Result ID Test Result Name Result LOINC Value
609995 Interpretation 83056-2
609996 Participated in the Interpretation No LOINC Needed
609997 Report electronically signed by 19139-5
609998 Material Received 81178-6
609999 Disclaimer 62364-5
610000 Case Number 80398-1
Mayo Clinic Laboratories | IHC Catalog Additional Information: